What is Stem Cell International?
Headquartered in Toledo, Ohio, Stem Cell International operates at the intersection of biotechnology and patient-centric healthcare. Since its inception in 2015, the organization has specialized in adult stem cell regenerative medicine, specifically targeting inflammatory and degenerative conditions. Their service portfolio, which includes advanced stem cell therapy and platelet-rich plasma (PRP) treatments, is designed to address chronic pain associated with sports injuries, hip, knee, and shoulder degradation. By offering a model that emphasizes affordability and clinical transparency, the company has carved out a distinct market position, effectively bridging the gap between experimental biotechnology and practical, accessible patient care for individuals seeking alternatives to traditional surgical interventions.
How much funding has Stem Cell International raised?
Stem Cell International has raised a total of $42K across 1 funding round:
Debt
$42K
Debt (2021): $42K with participation from PPP
Key Investors in Stem Cell International
PPP
Public-Private Partnership
What's next for Stem Cell International?
With the infusion of this recent capital, Stem Cell International is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on expanding its clinical footprint and enhancing its service delivery infrastructure to accommodate a broader patient demographic. As the firm transitions through its current Series B/C stage, management will likely prioritize the optimization of its regenerative protocols and the scaling of its consultation-to-treatment pipeline. This phase of development is critical for establishing long-term operational sustainability and reinforcing the company's competitive advantage in the rapidly evolving landscape of orthopedic recovery and regenerative health services.
See full Stem Cell International company page
